247 related articles for article (PubMed ID: 19383782)
1. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer.
Zhang M; Yao Z; Dubois S; Ju W; Müller JR; Waldmann TA
Proc Natl Acad Sci U S A; 2009 May; 106(18):7513-8. PubMed ID: 19383782
[TBL] [Abstract][Full Text] [Related]
2. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.
Zhang M; Ju W; Yao Z; Yu P; Wei BR; Simpson RM; Waitz R; Fassò M; Allison JP; Waldmann TA
J Immunol; 2012 Jun; 188(12):6156-64. PubMed ID: 22593619
[TBL] [Abstract][Full Text] [Related]
3. IL15 and Anti-PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors.
Chen W; Bamford RN; Edmondson EF; Waldmann TA
Clin Cancer Res; 2022 May; 28(10):2082-2093. PubMed ID: 35262675
[TBL] [Abstract][Full Text] [Related]
4. A very long-acting IL-15: implications for the immunotherapy of cancer.
Hangasky JA; Chen W; Dubois SP; Daenthanasanmak A; Müller JR; Reid R; Waldmann TA; Santi DV
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101947
[TBL] [Abstract][Full Text] [Related]
5. IL-15 in the Combination Immunotherapy of Cancer.
Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
Front Immunol; 2020; 11():868. PubMed ID: 32508818
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma.
Honeychurch J; Glennie MJ; Johnson PW; Illidge TM
Blood; 2003 Aug; 102(4):1449-57. PubMed ID: 12714523
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.
Turner JG; Rakhmilevich AL; Burdelya L; Neal Z; Imboden M; Sondel PM; Yu H
J Immunol; 2001 Jan; 166(1):89-94. PubMed ID: 11123280
[TBL] [Abstract][Full Text] [Related]
8. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
Yu P; Steel JC; Zhang M; Morris JC; Waldmann TA
Clin Cancer Res; 2010 Dec; 16(24):6019-28. PubMed ID: 20924130
[TBL] [Abstract][Full Text] [Related]
10. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
[TBL] [Abstract][Full Text] [Related]
11. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.
Lum HD; Buhtoiarov IN; Schmidt BE; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Leukoc Biol; 2006 Jun; 79(6):1181-92. PubMed ID: 16565324
[TBL] [Abstract][Full Text] [Related]
12. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
[TBL] [Abstract][Full Text] [Related]
13. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ
Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
16. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.
Tutt AL; O'Brien L; Hussain A; Crowther GR; French RR; Glennie MJ
J Immunol; 2002 Mar; 168(6):2720-8. PubMed ID: 11884438
[TBL] [Abstract][Full Text] [Related]
17. Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.
Medina-Echeverz J; Ma C; Duffy AG; Eggert T; Hawk N; Kleiner DE; Korangy F; Greten TF
Cancer Immunol Res; 2015 May; 3(5):557-66. PubMed ID: 25637366
[TBL] [Abstract][Full Text] [Related]
18. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
19. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.
Kim PS; Kwilas AR; Xu W; Alter S; Jeng EK; Wong HC; Schlom J; Hodge JW
Oncotarget; 2016 Mar; 7(13):16130-45. PubMed ID: 26910920
[TBL] [Abstract][Full Text] [Related]
20. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance.
Kobayashi H; Dubois S; Sato N; Sabzevari H; Sakai Y; Waldmann TA; Tagaya Y
Blood; 2005 Jan; 105(2):721-7. PubMed ID: 15367431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]